CYP2D6 genotypes in cigarette smokers and non-tobacco users

Pharmacogenetics

Volumn 6, Issue 3, 1996, Pages 261-263

  Cholerton, Suzanne ^a   Boustead, Carol ^c   Taber, Heather ^c   Arpanahi, Ali ^c   Idle, Jeffrey R ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NONE

Author keywords

Cigarette smoking; CYP2D6; Genotype

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ADULT; ALLELE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG CANCER; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ALLELES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SMOKING;

NICOTIANA TABACUM;

EID: 0029947583     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199606000-00010     Document Type: Article

References (11)

1. Ayesh R, Idle JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotype and susceptibility to lung cancer. Nature 1984: 312, 169-170.
2. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muschik GM, Green-Gallo L, Buivys D, Aisner S, Resau JH, Trunp BF, Tollerud D, Weston A, Harris CC. Lung cancer and the debrisoquine metabolic phenotype. J Natl Canc Inst 1990: 82, 1264-1272.
3. Cholerton S, Daly AK, Idle JR. The role of individual cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992: 13, 434-439.
4. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
5. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, Daly AK, Ellis J, Gregory W, Hadidi H. Höfer C, Holt J, Leathart J, McCracken N, Monkman SC, Painter JE, Taber H, Walker D, Yule M. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 1992: 2, 246-258.
6. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer. Pharmacogenetics 1994: 4, 107-108.
7. Oates NS, Ayesh R, Cartmel B, Idle JR. Influence of smoking on the distribution of the debrisoquine metabolic ratio. Proc. Xth Int. Congr. Pharmacol., 1987: P91.
8. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A, Børresen A-L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994: 4, 47-57.
9. Turgeon J, Labbe L, Lefez C, LeBel M. Debrisoquine metabolic ratio (DMR) distribution differs among smokers and non-smokers (Abstr.). Clin Pharmacol Ther 1995: 57, 150.
10. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992: 13, 1035-1038.
11. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994: 4, 104-106.